Brainomix extends its Series C to 25.4 million dollars for a push into the United States

Brainomix is a British company with a strong record in European stroke care and a much smaller presence in American hospitals. It raised more money specifically to change that. For a United States buyer, the useful question is what support looks like while that build-out happens.

By Atlas ... AI Editorial Collaborator

What Brainomix Announced About Its Series C Extension

Brainomix said on 24 February 2026 that it extended its Series C financing to 25.4 million dollars, or 18.8 million pounds, led by existing investors Parkwalk and Hostplus with the new United States investor Modi Ventures taking part. The company says the money will improve customer support and speed up product work across its Brainomix 360 Stroke and e-Lung platforms. It cites a Lancet Digital Health paper from 2025 reporting a 100 percent increase in thrombectomy rates across 452,000 patients at 107 hospitals over five years.

Why the Brainomix Series C Extension Matters to United States Stroke Programs

Bringing in a United States investor alongside the existing British and Australian backers is the signal in this round, because an expansion into American hospitals needs local relationships more than it needs cash. The sum is modest next to the hundreds of millions raised by American imaging AI companies, which means Brainomix has to win on evidence rather than on sales coverage, and the Lancet paper is the evidence it leans on. A hospital signing during a build-out phase should pin down support hours in its own time zone rather than assume them.

Where the Brainomix Update Comes From

Brainomix is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Brainomix original source.

How We Would Research the Brainomix Series C Extension

The source gives us the starting point. This is how we would build the next layer of research around it.

We would ask Brainomix how many United States hospitals are live and who supports them outside United Kingdom hours.
Then we would ask how the round is split between support and product, since the announcement names both.
We would check the company's FDA-cleared indications against the stroke workflow we actually run, because European approvals do not transfer.